HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

627.079

+14.1902.32%

Number of Gainers:23

Number of Losers:6

Number of Flat:5

PE:- -

High:631.140

Open:615.021

Low:615.021

Close:612.889

Volume:104.37M

Turnover:2.79B

Market Cap:385.64B

Float Cap:345.61B

Loading ...

IPO Preview | Weijian Pharma: Doubling H1 2025 Revenue Ahead of Listing

The Bull Case For Akeso (SEHK:9926) Could Change Following New Oncology Pipeline Milestones and Clinical Results

Simply Wall St.

Hong Kong Stocks Movement | WUXI XDC (02268) Rises Over 5% Before Noon as Overseas Innovative Drug Deals Expand and Order Momentum Remains Strong

ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development

Innovative Drug Concept Stocks Show Volatility, Nanjing Xinjiekou Hits Two Consecutive Limit-Ups

Pharmaceutical Sector Boosted as FDA Leadership Change Restores Market Confidence, Drug Stocks Hit Record Highs

Innovative Drug Companies Poised for Significant Liquidity Improvement

ASCLETIS-B (01672): Monthly-Dose Next-Gen Amylin Receptor Agonist ASC36 and GLP-1R/GIPR Dual-Target Agonist ASC35 Combo Advances to Clinical Development

JACOBIO-B (01167) Appoints Wang Yi as Co-Chief Executive Officer

Jacobio Pharmaceuticals Appoints Dr. Andrea Wang-Gillam as Co-CEO

Everest Medicines (SEHK:1952) Valuation Spotlight as New Ophthalmology Deal Expands Growth Prospects

Simply Wall St.

KINTOR PHARMA-B (09939) Plans to Issue 30.4875 Million Subscription Shares at 15.03% Discount, Raising Approximately HK$49.78 Million

BRIEF-Kintor Pharmaceutical To Allot And Issue Aggregate 30.5 Mln Shares At HK$1.64 Per Share

Kintor Pharmaceutical Announces Private Placement of New Shares

Kintor Pharmaceutical - to Allot and Issue Aggregate 30.5 Mln Shares at Subscription Price HK$1.64 per Share

THOMSON REUTERS

IMMUNOTECH-B (06978): Rights Issue Oversubscribed by Approximately 522.71%

Domestic Innovative Drugs Break Through, Offering a "Chinese Solution" for Influenza

Innovative Drug Leader Enters "Harvest Season"! Sector Heat Reignites, High-Popularity HK Stock Connect Innovative Drug ETF (520880) Surges 3% with Heavy Volume, Breaking Through Key Moving Averages

Ministry of Industry and Information Technology Seeks Public Feedback on Draft "National Medical Reserve Management Measures"

Shanghai United Imaging Healthcare (688271.SH) Subsidiary Obtains Medical Device Registration Certificate for Color Doppler Ultrasound Diagnostic System

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":627.0787,"timestamp":1763021314092,"preClose":612.88885,"halted":0,"volume":104373100,"delay":0,"changeRate":0.023152,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":14.189819,"latestTime":"11-13 16:00:00","open":615.02124,"high":631.1397,"low":615.02124,"amount":2792399983,"amplitude":0.026299,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1763083800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1762997400000,1763006400000],[1763010000000,1763020800000]],"pbRate":5.349541,"peRate":-44.158668,"turnoverRate":0.003801,"increases":23,"decrements":7,"flats":3,"marketCap":385644539840,"floatMarketCap":345608044416},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":631.1397,"amplitude":0.026299,"preClose":612.88885,"low":615.02124,"pbRate":"5.349541","latestPrice":627.0787,"volume":104373100,"delay":0,"open":615.02124,"prevYearClose":331.1933,"prevWeekClose":587.579,"prevMonthClose":618.706,"prevQuarterClose":752.859,"fiveDayClose":608.991,"twentyDayClose":659.471,"sixtyDayClose":840.007,"secType":"PLATE","market":"HK","turnoverRate":0.003801,"peRate":-44.158668,"marketCap":385644539840,"floatMarketCap":345608044416,"timestamp":1763021314092,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":23,"down":6,"flat":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1126925116","title":"IPO Preview | Weijian Pharma: Doubling H1 2025 Revenue Ahead of Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=1126925116","media":"Stock News","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126925116?lang=en_us&edition=fundamental","pubTime":"2025-11-13 14:46","pubTimestamp":1763016389,"startTime":"0","endTime":"0","summary":"Weijian Pharma, China's leading pharmaceutical company with the largest portfolio of commercialized innovative drugs for kidney diseases, has filed for its Hong Kong IPO. On November 7, the company...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1574","159938","BK1515","BK1161"],"gpt_icon":0},{"id":"2583373505","title":"The Bull Case For Akeso (SEHK:9926) Could Change Following New Oncology Pipeline Milestones and Clinical Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583373505","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583373505?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:49","pubTimestamp":1763009381,"startTime":"0","endTime":"0","summary":"In early November 2025, Akeso announced a series of pipeline milestones, including the first patient dosing in a Phase I trial of its mRNA vaccine AK154, the presentation of promising Overall Survival results for ivonescimab in EGFR-mutated non-small cell lung cancer at SITC, and new preclinical data for its novel antibody AK135.\nThe rapid progress across both late-stage and innovative early-stage assets underscores Akeso's efforts to expand its oncology portfolio while solidifying its...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/the-bull-case-for-akeso-sehk9926-could-change-following-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/the-bull-case-for-akeso-sehk9926-could-change-following-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348784397.USD","IE00B543WZ88.USD","LU0417516902.SGD","BK1574","LU2476274720.SGD","LU1720050803.USD","LU1961090484.USD","LU2476274308.USD","LU1794554557.SGD","LU2488822045.USD","LU0417516738.SGD","LU0348735423.USD","LU0417516571.SGD","LU0348827113.USD","LU2399975544.HKD","LU0634319403.HKD","09926","LU2778985437.USD","LU0348825331.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0561508036.HKD","LU0348766576.USD","LU0540923850.HKD","IE00BPRC5H50.USD","BK1161"],"gpt_icon":0},{"id":"1173585287","title":"Hong Kong Stocks Movement | WUXI XDC (02268) Rises Over 5% Before Noon as Overseas Innovative Drug Deals Expand and Order Momentum Remains Strong","url":"https://stock-news.laohu8.com/highlight/detail?id=1173585287","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173585287?lang=en_us&edition=fundamental","pubTime":"2025-11-13 11:46","pubTimestamp":1763005575,"startTime":"0","endTime":"0","summary":"WUXI XDC (02268) surged over 5% before noon, with a gain of 4.89% at the time of writing, trading at HK$70.8 and a turnover of HK$145 million. According to recent analysis, the MSCI China Healthcare...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","02268","159992","SG9999014674.SGD","BK1161","06978","BK1574","BK1141"],"gpt_icon":0},{"id":"1190620025","title":"ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1190620025","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190620025?lang=en_us&edition=fundamental","pubTime":"2025-11-13 10:30","pubTimestamp":1763001025,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01477","BK1161","BK1574","BK1191","01672"],"gpt_icon":0},{"id":"1179783504","title":"Innovative Drug Concept Stocks Show Volatility, Nanjing Xinjiekou Hits Two Consecutive Limit-Ups","url":"https://stock-news.laohu8.com/highlight/detail?id=1179783504","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179783504?lang=en_us&edition=fundamental","pubTime":"2025-11-13 10:00","pubTimestamp":1762999222,"startTime":"0","endTime":"0","summary":"On November 13, innovative drug concept stocks exhibited fluctuating activity, with Nanjing Xinjiekou Department Store Co., Ltd. (600682) securing two consecutive trading limit-ups. BeiGene (BGNE)...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0042","BK0113","BK0060","BK0093","BK1574","06978","BK0114","BK0196","159992","BK0070","BK0209","600682","BK1161","BK0183","BK0239"],"gpt_icon":0},{"id":"1185751714","title":"Pharmaceutical Sector Boosted as FDA Leadership Change Restores Market Confidence, Drug Stocks Hit Record Highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1185751714","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185751714?lang=en_us&edition=fundamental","pubTime":"2025-11-13 09:20","pubTimestamp":1762996824,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration (FDA) announced the appointment of Richard Pazdur, its top cancer drug reviewer, as Director of the Center for Drug Evaluation and Research, driving global...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1161","09939","01477","159938","BK1574","BK1515"],"gpt_icon":0},{"id":"1104578701","title":"Innovative Drug Companies Poised for Significant Liquidity Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=1104578701","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104578701?lang=en_us&edition=fundamental","pubTime":"2025-11-13 09:11","pubTimestamp":1762996263,"startTime":"0","endTime":"0","summary":"As the year-end approaches, a review of non-HK Connect (non-Hong Kong Stock Connect) biotech companies' performance this year reveals that, beyond fundamental factors, these assets have generally...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159992","BK1161","06978"],"gpt_icon":0},{"id":"1162352611","title":"ASCLETIS-B (01672): Monthly-Dose Next-Gen Amylin Receptor Agonist ASC36 and GLP-1R/GIPR Dual-Target Agonist ASC35 Combo Advances to Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1162352611","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162352611?lang=en_us&edition=fundamental","pubTime":"2025-11-13 07:36","pubTimestamp":1762990584,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that its monthly-dose next-generation amylin receptor agonist ASC36 and GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered clinical development. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK4144","GIPR","BK4160","BK1161","BK1515","01477","BK1191","GLP","01672","BK1574"],"gpt_icon":0},{"id":"1100159944","title":"JACOBIO-B (01167) Appoints Wang Yi as Co-Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1100159944","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100159944?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:40","pubTimestamp":1762987214,"startTime":"0","endTime":"0","summary":"JACOBIO-B (01167) announced that to further advance the group's global strategic layout and enhance cross-regional operational efficiency, the board of directors has approved the establishment of a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01167","BK1574"],"gpt_icon":0},{"id":"2583860535","title":"Jacobio Pharmaceuticals Appoints Dr. Andrea Wang-Gillam as Co-CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2583860535","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583860535?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:11","pubTimestamp":1762985476,"startTime":"0","endTime":"0","summary":"Jacobio Pharmaceuticals Group Co. Ltd. has appointed Dr. Andrea Wang-Gillam as Co-Chief Executive Officer. Dr. Wang-Gillam, who previously served as Chief Medical Officer and Senior Vice President, will focus on business development and operational management in global markets. Dr. Wang Yinxiang will remain as Chairman and Chief Executive Officer. The new Co-CEO structure is intended to strengthen the company's capabilities in global drug research, development, and commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL8V4QpJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01167"],"gpt_icon":0},{"id":"2583258658","title":"Everest Medicines (SEHK:1952) Valuation Spotlight as New Ophthalmology Deal Expands Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2583258658","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583258658?lang=en_us&edition=fundamental","pubTime":"2025-11-13 01:32","pubTimestamp":1762968779,"startTime":"0","endTime":"0","summary":"Everest Medicines (SEHK:1952) has announced a new agreement with Visara Inc., gaining exclusive rights to develop and commercialize VIS-101 across Greater China and parts of Asia. This deal marks Everest's move into ophthalmology and broadens its late-stage product pipeline.\nSee our latest analysis for Everest Medicines.\nEverest Medicines’ latest move into ophthalmology comes as the company’s momentum shifts, with the recent 1-year total shareholder return reaching an impressive 32.84%. The...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-spotlight-as-new-ophtha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-sehk1952-valuation-spotlight-as-new-ophtha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1583","01952","MDCO","BK1161"],"gpt_icon":0},{"id":"1163162327","title":"KINTOR PHARMA-B (09939) Plans to Issue 30.4875 Million Subscription Shares at 15.03% Discount, Raising Approximately HK$49.78 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1163162327","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163162327?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:00","pubTimestamp":1762959613,"startTime":"0","endTime":"0","summary":"KINTOR PHARMA-B (09939) announced on November 12, 2025, that the company intends to issue 30.4875 million subscription shares to Huayuan Management Consulting (Hong Kong) Limited, wholly owned by...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1515","09939"],"gpt_icon":0},{"id":"2582490370","title":"BRIEF-Kintor Pharmaceutical To Allot And Issue Aggregate 30.5 Mln Shares At HK$1.64 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2582490370","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582490370?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:57","pubTimestamp":1762959451,"startTime":"0","endTime":"0","summary":"BRIEF-Kintor Pharmaceutical To Allot And Issue Aggregate 30.5 Mln Shares At HK$1.64 Per ShareNov 12  - Kintor Pharmaceutical Ltd 9939.HK:TO ALLOT AND ISSUE AGGREGATE 30.5 MILLION SHARES AT SUBSCRIPTION PRICE HK$1.64 PER SHAREFurther company coverage: 9939.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO1EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2582370459","title":"Kintor Pharmaceutical Announces Private Placement of New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2582370459","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582370459?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:57","pubTimestamp":1762959442,"startTime":"0","endTime":"0","summary":"Kintor Pharmaceutical Ltd. has announced that it has entered into a subscription agreement on November 12, 2025, for the issuance of new shares under a general mandate. The agreement with the subscriber involves a private placement of shares, but the company notes that the subscription may or may not proceed to completion. Shareholders and potential investors are advised to exercise caution when dealing in the company's securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kintor Pharmaceutical Ltd. published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL3s6rmf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2582968370","title":"Kintor Pharmaceutical - to Allot and Issue Aggregate 30.5 Mln Shares at Subscription Price HK$1.64 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2582968370","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582968370?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:53","pubTimestamp":1762959205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO1EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","BK1515","09939"],"gpt_icon":0},{"id":"1189495251","title":"IMMUNOTECH-B (06978): Rights Issue Oversubscribed by Approximately 522.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189495251","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189495251?lang=en_us&edition=fundamental","pubTime":"2025-11-12 22:46","pubTimestamp":1762958777,"startTime":"0","endTime":"0","summary":"IMMUNOTECH-B (06978) announced that as of 4:00 PM on Tuesday, November 4, 2025 (the deadline for accepting rights shares and paying subscription fees, as well as applying for additional rights shares...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"1192172063","title":"Domestic Innovative Drugs Break Through, Offering a \"Chinese Solution\" for Influenza","url":"https://stock-news.laohu8.com/highlight/detail?id=1192172063","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192172063?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:50","pubTimestamp":1762951846,"startTime":"0","endTime":"0","summary":"According to the 881st issue of China's influenza surveillance weekly report (Week 44, 2025) by the Chinese Center for Disease Control and Prevention, as of November 2, 2025, influenza activity has...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06978","BK1161","159992"],"gpt_icon":0},{"id":"1106116921","title":"Innovative Drug Leader Enters \"Harvest Season\"! Sector Heat Reignites, High-Popularity HK Stock Connect Innovative Drug ETF (520880) Surges 3% with Heavy Volume, Breaking Through Key Moving Averages","url":"https://stock-news.laohu8.com/highlight/detail?id=1106116921","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106116921?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:40","pubTimestamp":1762947639,"startTime":"0","endTime":"0","summary":"The \"top player in innovative drugs\" leads the charge as Hong Kong's biotech sector stages a strong rebound! On November 12, the HK Stock Connect Innovative Drug ETF (520880), which holds 100%...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","520880","BK1574","06978","159992"],"gpt_icon":0},{"id":"1101597869","title":"Ministry of Industry and Information Technology Seeks Public Feedback on Draft \"National Medical Reserve Management Measures\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1101597869","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101597869?lang=en_us&edition=fundamental","pubTime":"2025-11-12 18:30","pubTimestamp":1762943432,"startTime":"0","endTime":"0","summary":"The Ministry of Industry and Information Technology (MIIT), through its Consumer Goods Industry Department, has revised the \"National Medical Reserve Management Measures (2021 Revision)\" (MIIT-Lian...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09939","159938","BK1574","BK1515"],"gpt_icon":0},{"id":"1131041555","title":"Shanghai United Imaging Healthcare (688271.SH) Subsidiary Obtains Medical Device Registration Certificate for Color Doppler Ultrasound Diagnostic System","url":"https://stock-news.laohu8.com/highlight/detail?id=1131041555","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131041555?lang=en_us&edition=fundamental","pubTime":"2025-11-12 17:50","pubTimestamp":1762941012,"startTime":"0","endTime":"0","summary":"Shanghai United Imaging Healthcare Co., Ltd. (688271.SH) announced that its wholly-owned subsidiary, Wuhan United Imaging Healthcare Technology Co., Ltd., received the Medical Device Registration...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK0251","BK1222","09996","BK1100","09997","159883","BK1583","688271"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":2,"totalSize":287,"code":"91000000","status":"200"}]}}